The Journal of infectious diseases
Population pharmacokinetic modeling of standard- and high-dose rifampicin for tuberculosis preventive therapy in the 2R2 randomized controlled trial.
Fajri Gafar, Elin M Svensson, Vycke Yunivita, Federica Fregonese, Dina Fisher, Greg J Fox, Thu Anh Nguyen, Binh Hoa Nguyen, James Johnston, Richard Long, Chantal Valiquette, Rob E Aarnoutse, Rovina Ruslami, Dick Menzies, 2R2 trial investigators
Published: 202610.1093/infdis/jiag052
Abstract
BACKGROUND: High-dose rifampicin could potentially shorten tuberculosis preventive therapy (TPT) and improve outcomes. We aimed to characterize population pharmacokinetics of standard- and high-dose rifampicin for TPT among individuals with tuberculo…
Preview only. Read the full abstract at the source